Herpetic esophagitis following bendamustine-containing regimen

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

A 76-year-old Japanese woman presented to our hospital with anorexia. Two years before, she was diagnosed with non-Hodgkin’s lymphoma and had received ten cycles of systemic chemotherapy. After salvage chemotherapy with bendamustine and rituximab (B–R), bone marrow suppression had lasted >3 months. Esophagogastroscopy revealed polynesic white protrusions in the mid-esophagus. These lesions were diagnosed as herpetic esophagitis. To the best of our knowledge, there is no other report in which herpetic esophagitis has been documented as an adverse event of B–R regimen. Because the complication could cause symptomatic gastrointestinal discomfort, physicians should be aware of this disease.

Cite

CITATION STYLE

APA

Yamane, H., Monobe, Y., Tanikawa, T., Ochi, N., Honda, Y., Kawamoto, H., & Takigawa, N. (2016). Herpetic esophagitis following bendamustine-containing regimen. Therapeutics and Clinical Risk Management, 12, 883–886. https://doi.org/10.2147/TCRM.S98217

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free